Myeloid-Derived Suppressor Cells in Human Cancer (Q37778697)

23 August 2017

1 reference

title

Myeloid-derived suppressor cells in human cancer (English)

1 reference

23 August 2017

Myeloid-Derived Suppressor Cells in Human Cancer (English)

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

18 June 2024

author

Dmitry I. Gabrilovich

2

object named as

Dmitry I. Gabrilovich

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20693846

18 June 2024

author name string

Srinivas Nagaraj

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20693846

18 June 2024

publication date

1 July 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/10.1097/PPO.0b013e3181eb3358

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

18 June 2024

1 reference

23 August 2017

volume

16

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

348-353

1 reference

Cell‐cycle regulation of T‐cell responses – novel approaches to the control of alloimmunity

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Tumor Escape from Immune Response: Mechanisms and Targets of Activity

18 June 2024

2

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species

18 June 2024

5

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Role of immature myeloid Gr-1+ cells in the development of antitumor immunity

18 June 2024

6

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice

18 June 2024

7

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation

18 June 2024

9

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

18 June 2024

10

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity

18 June 2024

11

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

18 June 2024

12

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

18 June 2024

13

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

18 June 2024

14

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Myeloid-derived suppressor cells as regulators of the immune system

18 June 2024

15

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

18 June 2024

16

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer

18 June 2024

17

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Tumor-induced immune dysfunctions caused by myeloid suppressor cells

18 June 2024

18

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Mechanisms and functional significance of tumour-induced dendritic-cell defects

18 June 2024

19

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells

18 June 2024

20

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

18 June 2024

21

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

18 June 2024

22

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

18 June 2024

23

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

18 June 2024

24

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

18 June 2024

25

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

18 June 2024

26

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer

18 June 2024

27

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells

18 June 2024

28

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

18 June 2024

29

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum

18 June 2024

31

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

18 June 2024

32

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses

18 June 2024

33

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

18 June 2024

34

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism.

18 June 2024

35

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice

18 June 2024

36

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells

18 June 2024

37

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

18 June 2024

38

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

18 June 2024

39

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion

18 June 2024

40

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

18 June 2024

41

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine

18 June 2024

42

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host

18 June 2024

43

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells

18 June 2024

44

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

The adaptive immune response to sporadic cancer

18 June 2024

45

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer

18 June 2024

46

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Signaling defects in anti-tumor T cells

18 June 2024

47

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells

18 June 2024

48

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

18 June 2024

49

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression

18 June 2024

50

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Suppressive influences in the immune response to cancer

18 June 2024

51

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

18 June 2024

52

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells

18 June 2024

53

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

18 June 2024

54

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Subsets of myeloid-derived suppressor cells in tumor-bearing mice

18 June 2024

55

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Reactive oxygen species production by blood neutrophils of patients with laryngeal carcinoma and antioxidative enzyme activity in their blood.

18 June 2024

56

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Reactive oxygen species: role in the development of cancer and various chronic conditions

18 June 2024

57

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress

18 June 2024

58

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Non-irradiation-derived reactive oxygen species (ROS) and cancer: therapeutic implications

18 June 2024

59

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

18 June 2024

60

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Quantitative analysis of vascular endothelial growth factor in primary breast cancer

18 June 2024

61

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Angiogenesis and metastasis

18 June 2024

62

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

18 June 2024

64

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

18 June 2024

65

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.

18 June 2024

66

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

18 June 2024

67

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers

18 June 2024

68

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor.

18 June 2024

69

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor

18 June 2024

70

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells

18 June 2024

71

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination.

18 June 2024

72

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy

18 June 2024

73

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

18 June 2024

74

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses

18 June 2024

76

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

18 June 2024

77

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

18 June 2024

78

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

18 June 2024

79

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

18 June 2024

80

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

18 June 2024

81

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

18 June 2024

82

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

18 June 2024

83

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma

18 June 2024

84

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion

18 June 2024

85

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

18 June 2024

86

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer.

18 June 2024

87

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Resection of solid tumors reverses T cell defects and restores protective immunity

18 June 2024

89

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice

18 June 2024

90

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis.

18 June 2024

92

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

18 June 2024

93

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function

18 June 2024

94

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181EB3358

18 June 2024

Identifiers

1 reference

23 August 2017

1 reference